August 2003 in “Oncology Times” The trial on testosterone replacement therapy in older men faced concerns due to prostate cancer risk.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
1 citations
,
April 2008 in “Progrès en Urologie” Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
9 citations
,
February 2022 in “Biomolecules” Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.
6 citations
,
June 2009 in “Journal of Clinical Oncology” 5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.